Provexis plc logo

Provexis plc (NZCA)

Market Closed
11 Aug, 06:03
XFRA XFRA
0. 01
+0
+5.5556%
- Market Cap
- P/E Ratio
- Div Yield
22,000 Volume
- Eps
0.01
Previous Close
Add Transaction
Day Range
0.01 0.01
Year Range
0 0.02
Want to track NZCA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NZCA closed yesterday higher at €0.01, an increase of 5.5556% from Monday's close, completing a monthly decrease of -13.6364% or €0. Over the past 12 months, NZCA stock gained 35.7143%.
NZCA is not paying dividends to its shareholders.
The last earnings report, released on Dec 29, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

NZCA Chart

Provexis plc (NZCA) FAQ

What is the stock price today?

The current price is €0.01.

On which exchange is it traded?

Provexis plc is listed on XFRA.

What is its stock symbol?

The ticker symbol is NZCA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Provexis plc ever had a stock split?

No, there has never been a stock split.

Provexis plc Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Ian Ford BA (Hons) ACA, F.C.A. CEO
XFRA Exchange
GB00B0923P27 ISIN
United Kingdom Country
2 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Provexis plc operates as a pioneering entity focused on the invention, licensing, and commercial distribution of functional foods, medical foods, and dietary supplements with a global outreach. Established in 1999 and headquartered in Reading, the United Kingdom, the company has carved a niche in the health and wellness sector by developing innovative products aimed at improving cardiovascular health and overall well-being. It primarily caters to consumer needs through comprehensive distribution channels, including partnerships with distributors and online retail platforms, ensuring wide accessibility to its health-boosting offerings.

Products and Services

  • Fruitflow: A clinically proven tomato extract designed to diminish the risk of abnormal blood clotting, a common precursor to serious cardiovascular ailments such as heart attacks and strokes. This flagship product underscores Provexis plc's commitment to cardiovascular health by naturally supporting smoother blood flow.
  • The product has been refined into syrup and powder formulations, enabling versatile applications across a myriad of food, beverage, and dietary supplement products. Its adaptability and efficacy make it a sought-after ingredient for health-conscious consumers and brands alike.

  • Fruitflow + Omega-3: Building on the foundational benefits of Fruitflow, this enhanced formulation synergistically combines the blood flow-promoting effects of Fruitflow with the cardiovascular health benefits of Omega-3 fatty acids. Available in capsule form, this supplement is tailored for individuals looking to bolster their heart function and maintain healthy circulation.
  • Through its innovative approach to product development and keen focus on heart health, Provexis plc offers solutions that align with the growing consumer demand for natural and effective dietary supplements. The company leverages both direct and indirect sales channels to reach a global audience, ensuring that its health-enhancing products are accessible to a wide customer base.

Contact Information

Address: I Ford
Phone: 44 7490 391888